Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis. An Randomised, Crossover Pilot Study of AZLI Plus Intravenous Colistin® Versus Standard Dual Intravenous Therapy

NCT02894684 is registered in ClinicalTrials.gov with Liverpool Heart and Chest Hospital NHS Foundation Trust as lead sponsor.

NCT NCT02894684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02894684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis. An Randomised, Crossover Pilot Study of AZLI Plus Intravenous Colistin® Versus Standard Dual Intravenous Therapy
Lead sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2017
Completion date
September 30, 2019
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis, infection, pseudomonas